Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04660344
Recruitment Status : Recruiting
First Posted : December 9, 2020
Last Update Posted : April 19, 2021
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.

Condition or disease Intervention/treatment Phase
Muscle-invasive Bladder Cancer Drug: Atezolizumab Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 495 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
Estimated Study Start Date : April 30, 2021
Estimated Primary Completion Date : November 1, 2023
Estimated Study Completion Date : April 16, 2029

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Arm Intervention/treatment
Experimental: Arm A: Atezolizumab
Atezolizumab will be administered intravenously at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
Drug: Atezolizumab
Participants will receive 1680 mg intravenously every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
Other Name: Tecentriq

Placebo Comparator: Arm B: Placebo
Placebo will be administered intravenously on Day 1 of each 28-day cycle. Placebo will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
Other: Placebo
Participants will receive placebo intravenously Q4W on Day 1 of each 28-day cycle




Primary Outcome Measures :
  1. IRF-assessed DFS in Participants Who Are ctDNA Positive Within 20 Weeks of Cystectomy [ Time Frame: Randomization up to first occurrence of DFS event (up to approximately 73 months) ]

    Independent Review Facility(IRF)-assessed disease-free survival (DFS) in participants who are ctDNA positive within 20 weeks of cystectomy (primary analysis population), defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following:

    • Local (pelvic) recurrence of urothelial carcinoma (UC) (including soft tissue and regional lymph nodes)
    • Urinary tract recurrence of UC (including all pathological stages and grades)
    • Distant metastasis of UC
    • Death from any cause


Secondary Outcome Measures :
  1. Overall survival (OS) in Participants Who Are ctDNA Positive Within 20 weeks After Cystectomy [ Time Frame: Randomization up to death from any cause (up to approximately 73 months) ]
    Overall survival (OS) in participants who are ctDNA positive within 20 weeks after cystectomy (primary analysis population), defined as the time from randomization to death from any cause.

  2. IRF-assessed DFS in All Randomized Participants [ Time Frame: Randomization up to first occurrence of DFS event (up to approximately 73 months) ]
  3. Investigator-Assessed DFS in Primary Analysis Population [ Time Frame: Randomization up to first occurrence of DFS event (up to approximately 73 months) ]
  4. Investigator-Assessed DFS in All Randomized Participants [ Time Frame: Randomization up to first occurrence of DFS event (up to approximately 73 months) ]
  5. Investigator-Assessed Disease-Specific Survival in Primary Analysis Population [ Time Frame: Randomization to death from UC (up to approximately 73 months) ]
    Investigator-assessed disease-specific survival in the primary analysis population, defined as the time from randomization to death from UC per investigator assessment of cause of death.

  6. Investigator-Assessed Distant Metastasis-Free Survival in Primary Analysis Population [ Time Frame: Randomization to diagnosis of distant metastases or death from any cause (up to approximately 73 months) ]
    Investigator-assessed distant metastasis-free survival in the primary analysis population, defined as the time from randomization to the diagnosis of distant (i.e., non-locoregional) metastases or death from any cause.

  7. Time to Deterioration of Function and Quality of Life (QoL) in Primary Analysis Population and in All Randomized Population [ Time Frame: Randomization to participant's first score decrease of >=10 points from Baseline on EORTC QLQ-C30 physical function scale, role function scale, and the GHS/QoL Scale (up to approximately 73 months) ]
    Time to deterioration of function and quality of life (QoL) in the primary analysis population and in the all randomized population, defined as the time from randomization to the date of a participants's first score decrease of >= 10 points from baseline on the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) physical function scale, role function scale, and the global health status (GHS)/QoL scale (separately).

  8. ctDNA Clearance in Primary Analysis Population [ Time Frame: Baseline, Cycle 3 Day 1 or Cycle 5 Day 1 (each cycle is 28 days) ]
    ctDNA clearance in the primary analysis population, defined as the proportion of patients who are ctDNA positive at baseline and ctDNA negative at Cycle 3, Day 1 or Cycle 5, Day 1.

  9. Percentage of Participants With Adverse Events [ Time Frame: Baseline up to approximately 73 months ]
  10. Serum Concentration of Atezolizumab [ Time Frame: At pre-defined intervals from first administration of study drug up to approximately 73 months ]
  11. Incidence of Anti-Drug Antibodies (ADAs) to Atezolizumab [ Time Frame: Baseline up to approximately 73 months ]
    Incidence of anti-drug antibodies (ADAs) to atezolizumab during the study.

  12. Prevalence of ADAs to Atezolizumab [ Time Frame: Baseline ]
    Prevalence of ADAs to atezolizumab at baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for the Surveillance Phase:

  • Histologically confirmed MIUC (also termed TCC) of the bladder
  • TNM classification (based on AJCC Cancer Staging Manual, 7th Edition; Edge et al. 2010) at pathological examination of surgical resection specimen as follows: For patients treated with prior NAC: tumor stage of ypT2-4a or ypN+ and M0. For patients who have not received prior NAC: tumor stage of pT3-4a or pN+ and M0
  • Surgical resection of MIUC of the bladder
  • Patients who have not received prior platinum-based NAC, have refused, or are ineligible ("unfit") for cisplatin-based adjuvant chemotherapy
  • ctDNA assay developed based on tumor tissue specimen and matched normal DNA from blood.
  • Tumor PD-L1 expression per IHC and confirmed diagnosis of MIUC as documented through central testing of a representative tumor tissue specimen
  • Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan of the pelvis, abdomen, and chest no more than 4 weeks prior to enrollment.
  • Full recovery from cystectomy and enrollment within 14 weeks following cystectomy. Minimum of 6 weeks must have elapsed from surgery.

Additional Inclusion Criteria for the Treatment Phase:

  • Plasma sample evaluated to be ctDNA positive
  • Absence of residual disease and absence of metastasis, as confirmed by a negative baseline CT or MRI scan of the pelvis, abdomen, and chest no more than 4 weeks prior to randomization.
  • ECOG Performance Status of <= 2
  • Life expectancy >=12 weeks
  • Adequate hematologic and end-organ function
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception and agreement to refrain from donating eggs

General Medical Exclusion Criteria:

  • Pregnancy or breastfeeding
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
  • History of autoimmune disease. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study. Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen may be eligible for this study.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Positive test for HIV
  • Patients with active hepatitis B virus or hepatitis C
  • Active tuberculosis
  • Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina

Cancer-Specific Exclusion Criteria:

  • Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to study enrollment
  • Adjuvant chemotherapy or radiation therapy for UC following cystectomy
  • Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or 5 half-lives of the drug, whichever is longer, prior to enrollment
  • Malignancies other than UC within 5 years prior to study enrollment

Additional Exclusion Criteria for the Treatment Phase:

  • Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to randomization to the treatment phase Hormone-replacement therapy or oral contraceptives are allowed.
  • Adjuvant chemotherapy or radiation therapy for UC following cystectomy
  • Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or 5 half-lives of the drug, whichever is longer, prior to randomization to the treatment phase

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04660344


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: BO42843 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global.rochegenentechtrials@roche.com

Locations
Show Show 164 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT04660344    
Other Study ID Numbers: BO42843
First Posted: December 9, 2020    Key Record Dates
Last Update Posted: April 19, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here ( https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Atezolizumab
Antineoplastic Agents